5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS
申请人:Hutchinson H. John
公开号:US20070105866A1
公开(公告)日:2007-05-10
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.
[EN] COMPOUNDS FOR SEPARATION OF RARE EARTH ELEMENTS AND S-, P-, D- METALS, METHOD OF SEPARATION, AND USE THEREOF<br/>[FR] COMPOSÉS POUR LA SÉPARATION D'ÉLÉMENTS DE TERRES RARES ET DE MÉTAUX S-, P-, D-, PROCÉDÉ DE SÉPARATION ET UTILISATION DE CEUX-CI
申请人:USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I
公开号:WO2019106182A1
公开(公告)日:2019-06-06
The present invention relates to compounds of general formula (I) for chromatographic separation of rare earth elements and/or s-, p-, d- metals, as well as to the method of the separation of rare earth elements.
本发明涉及通式(I)化合物,用于稀土元素和/或s、p、d金属的色谱分离,以及稀土元素分离方法。
5-Lipoxygenase-Activating Protein (FLAP) Inhibitors
申请人:Hutchinson John H.
公开号:US20090221574A1
公开(公告)日:2009-09-03
Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.
Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A)
申请人:Leblond Bertrand
公开号:US08772316B2
公开(公告)日:2014-07-08
The invention relates to compounds of the formula
wherein R′, R1, through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A)
申请人:Allergan, Inc.
公开号:US20140309253A1
公开(公告)日:2014-10-16
The invention relates to compounds of the formula
wherein R′, R
1
through R
7
and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.